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Papillomaviruses induce benign and malignant epithelial tumors, and the viral E6 oncoprotein is
essential for full transformation. E6 contributes to transformation by associating with cellular proteins,
docking on speciﬁc acidic LXXLL peptide motifs found on these proteins. This review examines insights
from recent studies of human and animal E6 proteins that determine the three-dimensional structure of
E6 when bound to acidic LXXLL peptides. The structure of E6 is related to recent advances in the
puriﬁcation and identiﬁcation of E6 associated protein complexes. These E6 protein-complexes, together
with other proteins that bind to E6, alter a broad array of biological outcomes including modulation of
cell survival, cellular transcription, host cell differentiation, growth factor dependence, DNA damage
responses, and cell cycle progression.
& 2013 Elsevier Inc. All rights reserved.Introduction to papillomaviruses
Papillomaviruses are small encapsidated double-stranded DNA
viruses that induce benign squamous epithelial neoplasms called
papillomas in vertebrates, and replicate within the papilloma.
Although virus-induced papillomas are initially benign, some
may evolve over time to produce malignancies, an observation
ﬁrst made over 75 years ago (Rous and Beard, 1935). Medically, a
subset of human papillomaviruses (HPV) is notable for inducing
upper respiratory and ano-genital papillomas that can progress to
carcinomas; that subset of viruses is referred to as “high risk” HPV
types, and the related HPV viruses that cause benign papillomas
that do not progress to malignancy are called “low risk”.
This review is part of the Papillomavirus Episteme PAVE online
source for papillomavirus information (http://pave.niaid.nih.gov/
#home) and will be periodically updated with corrections and
new information, which can be emailed to the authors at E6.PAVE.
review@gmail.com. E6 has been the subject of other excellent
reviews recently (Fan and Chen, 2004; Klingelhutz and Roman,
2012; Li et al., 2005; Liu and Baleja, 2008; Narisawa-Saito and
Kiyono, 2007; Tungteakkhun and Duerksen-Hughes, 2008; Vande
Pol, 2012; Wise-Draper and Wells, 2008). This review focuses
upon the recently solved structure of E6 and its relation to the
proteomic identiﬁcation of E6 associated protein complexes, and
biological effects of E6.ll rights reserved.
iversity of Virginia, P.O. Box
34 924 2151.
e Pol).The papillomavirus life cycle
Papilloma formation and the infectious life cycle begins with an
injury to the cutaneous or mucosal squamous epithelium, expos-
ing the basement membrane and basal cell layer to virus (Fig. 1).
The viral DNA initially replicates as a plasmid to low copy numbers
in proliferative basal epithelial cells. When an infected basal cell
divides, the progeny cells may move laterally on the basement
membrane or up into the spinous cell layer where a subset of
these infected spinous cells aberrantly re-enter the cell cycle to
amplify viral DNAs from low to high copy number (Fig. 1 and
reviewed in (Chow et al., 2010)). As cells with ampliﬁed viral DNA
move to higher layers within the stratiﬁed epithelium they express
late gene capsid proteins to encapsidate viral DNA. Infectious virus
is released from the surface of the papilloma within desquamated
cells. This is unlike the uninfected adjacent squamous epithelium
where cells divide in the basal layer, but commit to a terminal
differentiation pathway upon moving into the spinous cell layer.
Three papillomavirus early gene products, termed E5, E6, and
E7, are proteins that stimulate cell proliferation, cell survival, and
modulate keratinocyte differentiation; these are oncoproteins. In
HPV associated cancers, continued E6 and E7 expression sustains
the continued cancer phenotype. When the HPV early promoter in
cervical cancer cell lines is repressed by re-expression of the viral
E2 transcriptional repressor or by RNAi mediated repression of
viral mRNA expression, cancer cell lines withdraw from the cell
cycle and terminally differentiate (Butz et al., 2003; Chen et al.,
1995b; Dowhanick et al., 1995; Francis et al., 2000; Goodwin and
DiMaio, 2000; Hamada et al., 1996; Hwang et al., 1993; Storey
et al., 1991; Tan and Ting, 1995; Thierry and Yaniv, 1987; von
Knebel Doeberitz et al., 1994; Yoshinouchi et al., 2003).
Fig. 1. The papillomaviruses life cycle. Papillomaviruses infect keratinocytes in the basal layer of the epithelium. Upon infection, the viral genome replicates to low-copy
episomes in the basal layer; upon cell division, a daughter cell will move up from the basal layer and undergo Notch dependent differentiation. Differentiation induces the
productive phase of the viral life cycle. The expression of viral oncoproteins induces re-entry of cells into S phase in the spinous layer, amplifying viral DNA copy number. A
subset of cells that ampliﬁed the viral genome will then express the late-phase L1 and L2 capsid proteins in the last layers of the epithelium, encapsidate viral genomes, and
are shed as cells containing virus.
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the three viral oncoproteins transform indicator cells like 3T3 cells,
although in other papillomaviruses such as the low risk alpha-
group mucosal papillomaviruses (such as HPV-6 or 11) such
transforming activity can be unapparent. In BPV-1, the E5 onco-
protein activates receptor tyrosine kinases in the Golgi region of
the cell in a ligand independent manner (reviewed in Talbert-
Slagle and DiMaio, 2009). In contrast, in HPV's an open reading
frame encoding E5 is sometimes not evident, and when E5 is
present, it has typically shown poor activity in classic transforma-
tion assays (Venuti et al., 2011). The E7 oncoproteins from diverse
papillomaviruses have more consistent activities, including asso-
ciations with cullin ubiquitin ligases and UBR4 (Demasi et al.,
2005; Huh et al., 2007, 2005; White et al., 2012b), a large ubiquitin
ligase that participates in the N-end rule protein degradation
pathway (Besche et al., 2009). Most E7 proteins have an LXCXE
binding motif that associates with members of the retinoblastoma
family of tumor suppressors, resulting in ubiquitin mediated
targeted degradation of the associated RB family members
(reviewed in McLaughlin-Drubin and Munger (2009)). However,
not all papillomavirus E7 oncoproteins associate with RB proteins
through LXCXE associations. For example, BPV-1 E7 does not
contain a LXCXE motif and, rarely, some papillomaviruses have
no E7 gene at all (isolates from domestic pigs, SsPV, polar bear
UmPV, and porpoises; Stevens et al., 2008a, 2008b; Van Bressem
et al., 2007).The evolution of E6
Phylogenetic analysis of papillomavirus genomes compared to
their host species has shown that each virus coevolved with its
host (Bernard, 1994; Chan et al., 1992; Tachezy et al., 2002).
Papillomaviruses are classiﬁed on the basis of the most conserved
L1 open reading frame, but diversity is enhanced in the E6–E7
oncogene region (Garcia-Vallve et al., 2005). Several papilloma-
viruses have no E6 gene at all (bovine papillomavirus types 3, 4, 6,
and HPV types 101 and 103; Chen et al., 2007; de Villiers et al.,
2004; Tachezy et al., 2002; Terai et al., 2002). Two avian papillo-
maviruses in contain an E6 gene with only one zinc-binding region
instead of two (Van Doorslaer et al., 2009). This suggests that a
progenitor papillomavirus genome with replication and capsid
proteins somehow acquired an E7 oncoprotein with a single zinc-
binding region. The zinc-binding region of E7 then may have
duplicated and subsequently diverged, giving rise to a single zinc
ﬁnger E6 protein similar to that found in avian species. A possible
additional early duplication of that E6 domain in reptiles (as seenwithin turtles) resulting in two zinc ﬁngers could have given
rise to the E6 protein most commonly observed today
(recently reviewed in Garcia-Vallve et al. (2005) and Shah et al.
(2010)). The E6 protein sequence and zinc domain fold are distinct
and do not resemble described cellular proteins (Nomine et al.,
2003).
The high-risk E6 and E7 proteins are typically expressed from a
common early promoter. As mentioned above, HrE7 proteins
interact with UBR4 and cullin family ubiquitin ligases, and contain
an LXCXE peptide-binding motif that binds to members of the
retinoblastoma family of proteins that regulate E2F family tran-
scription factors (reviewed in McLaughlin-Drubin and Munger
(2009)). While hrE7 are themselves oncogenic, E7 from low-risk
viruses are weakly oncogenic directly, and only have co-operative
activity when co-expressed with additional oncogenes from the
high-risk viruses (Halbert et al., 1992). This difference between
high and low risk E7 proteins has been explained by the observa-
tion that the hrE7 LXCXE motif differs from the low risk LXCXE
motif; while both hrE7 and low risk E7 bind to and then target the
degradation of the p130 RBL2 protein that regulates G0 to G1
transition in the cell cycle, only the hrE7 proteins also bind to and
target the degradation of p105 RB that controls G1 to S transition
(Zhang et al., 2006). Further, low risk E7 proteins can be rendered
oncogenic if the LXCXE motif of the low risk is mutated to the
high-risk sequence (Heck et al., 1992; Sang and Barbosa, 1992). The
targeted degradation of p105 RB by oncogenic E7 proteins results
in the stabilization of the p53 tumor suppressor protein and thus
sensitizes E7 expressing cells to apoptosis (Eichten et al., 2002;
Jones et al., 1997; Stoppler et al., 1998). Thus, for the hrE6 proteins
the “purpose” of E6 may be to neutralize the untoward conse-
quences of E7 transformation by blocking the function of p53 and
inhibiting cell cycle arrest and apoptosis. Consistent with this
notion, an examination of numerous hrE6 proteins showed that all
targeted the degradation of p53 (Fu et al., 2010). However, the
hrE7-RB+hrE6-p53 connection does not explain how most papil-
lomaviruses induce the replication of viral DNA in the spinous
layer of papillomas. For example, BPV-1 or the low risk mucosal
HPV papillomavirus E6 and E7 proteins induce cell cycle re-entry
in the spinous cell layer but do not target p105 RB or p53 for
degradation. Similarly, the E7 oncoprotein of cotton tailed rabbit
papillomavirus (CRPV) reduces RB expression levels in keratino-
cytes, but its E6 proteins do not target the degradation of p53, and
p53 is still inducible by mitomycin C in the presence of E6
(Ganzenmueller et al., 2008). Thus for most papillomaviruses,
how viral oncoproteins induce either the papilloma or the replica-
tion of virus within the papilloma is poorly understood.
Fig. 2. Known LXXLL binding motifs in E6 associated proteins. Hydrophobic
residues are in blue and acidic in red. The number refers to the ﬁrst amino acid
in the motif. The top grouping of LXXLL peptides interacts with BE6 and the bottom
two sequences are LXXLL peptides that interact with hrE6. PXN, NP_002850.2;
MAML1, NP_055572.1; MAML3, NP_061187.2; UBE3A, NP_570853.1; IRF3,
NP_001184051.1.
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Early studies focused upon BE6 and hrE6 proteins because they
caused quantitative focus formation or anchorage independent
colony formation in immortalized cell lines, while low risk E6
proteins had no quantiﬁable phenotypes. The ﬁrst physiologic
function for any E6 protein was the transformation of mouse C127
cells in tissue culture by BPV-1 E6 (Schiller et al., 1984) followed
shortly thereafter by the transformation of mouse 3T3 and rat-1
cells by high risk E6 and E7 (Bedell et al., 1987). These observations
were soon followed by studies demonstrating immortalization of
primary keratinocytes by high-risk E6+E7 (Hawley-Nelson et al.,
1989; Hudson et al., 1990; Ma et al., 1987; Munger et al., 1989;
Sedman et al., 1991; Woodworth et al., 1989). While the E7
oncoprotein from high risk HPV's immortalize keratinocytes at
low frequency, the E6 oncoproteins alone do not, but the combi-
nation of hrE6 and hrE7 immortalizes keratinocytes at high
frequency.
The ﬁrst quantitative in vitro assay for an E6 protein was the
association of hrE6 with p53 (Werness et al., 1990) and the
targeted degradation of p53 by hrE6 in rabbit reticulocyte lysate
(Scheffner et al., 1990). Both the transformation and p53 degrada-
tion assays provided quantitative results for studies of E6 mutants
and associated proteins. Additional quantitative assays for tran-
scriptional modulation, signal transduction and cell survival have
provided opportunities for the study of other HPV and animal
papillomavirus E6 proteins. The recent observation that cutaneous
E6 proteins repress cellular Notch signaling has provided another
system for quantitative analysis of cutaneous E6 biological activity
(Brimer et al., 2012; Rozenblatt-Rosen et al., 2012; Tan et al., 2012).Fig. 3. Ribbon diagram of 16E6 bound to the LXXLL motif from E6AP. In the left
upper panel, the amino-terminal zinc-binding domain (16E6-N in green) is shown
at the top and the helical LXXLL peptide (salmon color) is viewed on end from
the amino-terminus through its axis. The LXXLL peptide resides in a deep pocket.
The interdomain connecting helix (yellow) is clearly seen to the right side of the
right upper panel. The right lower panel is the same view as the right upper panel
but with the LXXLL peptide removed from the 16E6 pocket. The left lower panel is
rotated to show the dimerization domain that is located within the green 16E6-N
domain; the dimerization domain is colored purple (shown only in the lower left
image).Association of E6 with cellular proteins
We will see that E6 oncoproteins can interact with cellular
targets on distinct surfaces of E6, but the primary interaction seen
with mucosal and cutaneous HPV E6 and BE6 is to bind an alpha
helical acidic LXXLL peptide expressed as part of a cellular target
protein.
E6 binding to LXXLL peptides on target cellular proteins
Analysis of p53 degradation by 16E6 led to the identiﬁcation of
a cellular enzyme termed E6AP (E6 Associated Protein, the product
of the UBE3A gene), a HECT domain ubiquitin ligase that associates
with hrE6 and p53 (Huibregtse et al., 1993a). Mutagenesis of E6AP
showed that E6 bound to a 20 amino acid peptide in E6AP that
contained a LXXLL sequence. Subsequent work on BE6 identiﬁed
the BE6 associated protein paxillin (Tong et al., 1998; Tong and
Howley, 1997; Vande Pol et al., 1998) and identiﬁed LXXLL motifs
in paxillin where BE6 bound (Vande Pol et al., 1998). Mutagenesis
of the 20 amino acid E6AP peptide that bound 16E6 and mutagen-
esis of the paxillin peptide that bound BE6 more clearly deﬁned
the binding sequence as an acidic LXXLL peptide, shown in Fig. 2
along with additional peptides that interact with BE6 that will be
discussed below (Bohl et al., 2000; Chen et al., 1998). The strongest
conservation in the LXXLL peptides is observed for the hydro-
phobic positions L4, L7, and (F/L)8; i.e., LXXLL. Four positions in the
motif (3, 5, 6 and 10) show preferences for negative residues. We
will generically refer to E6 binding peptides as acidic LXXLL motifs.
In the crystal structure of BE6 discussed below, there are contacts
between BE6 and the LXXLL peptide over a 10 amino acid peptide
with the consensus sequence Φ1X2D3L4D5(D/E)]6L7(F/L)8X9(D/E)10.
The recent observation that cutaneous HPV E6 proteins and BE6
also interact with acidic motifs of MAML1 and MAML3 extend the
generality of the E6–LXXLL interaction, and the homology to the
E6AP LXXLL is striking (Fig. 3), but it is unclear as of yet if thebinding of E6 proteins to LXXLL motifs is universal to other animal
papillomavirus E6 oncoproteins, especially those with divergent
primary structures (such as avian E6 with only a single zinc
binding domain or the long cotton tail rabbit papillomavirus E6
with additional zinc binding domains).
E6 docking to LXXLL peptides is essential for BE6 and 16E6
function. First, mutants of E6 that fail to bind LXXLL are function-
ally defective; BE6 mutants that fail to bind to LXXLL-containing
target proteins fail to transform cells, and 16E6 mutants that fail to
bind to the E6AP LXXLL docking site fail to target the degradation
of p53 (Cooper et al., 2003; Das et al., 2000; Vande Pol et al., 1998;
Zanier et al., 2013). Second, deletion of the LXXLL motif in E6
target proteins ablates E6 function; deletion of LXXLL in E6AP both
prevents E6 association and E6 directed E6AP-mediated p53
degradation (Huibregtse et al., 1993b), while deletion of the BE6
binding motifs of paxillin prevents BE6 association and transfor-
mation (Wade et al., 2008). Third, blocking the LXXLL binding
pocket of E6 with an inhibitor blocks E6 function; fusion of a
LXXLL motif to the amino-terminus of BE6 binds to BE6 in cis and
blocks cellular transformation by BE6, and upon mutation of the
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potential artifacts due to mutation of BE6 itself (Bohl et al., 2000).
Fourth, peptides or drugs that competitively block 16E6 interac-
tions with LXXLL targets inhibit in vitro and in vivo p53 degrada-
tion by 16E6 (Baleja et al., 2006; Liu et al., 2004; Sterlinko Grm
et al., 2004).
In vitro E6 LXXLL binding assays are difﬁcult, possibly because
bacterially expressed E6 preparations contain aggregated E6 proteins
that have high non-speciﬁc binding. Even in vitro translated protein
has high non-speciﬁc binding, prompting the addition of non-ionic
detergents that (in our hands at least) degrades speciﬁc interactions
between hrE6 and LXXLL peptides. LXXLL interactions with E6 are
easily performed by yeast 2-hybrid assays (Cooper et al., 2003; Elston
et al., 1998; Vande Pol et al., 1998). In contrast to hrE6, BE6 is not
inhibited by non-ionic detergents, which has allowed for robust
in vitro binding assays (Das et al., 2000). LXXLL binding assays with
hrE6 proteins are possible, but require careful preparation and
puriﬁcation of hrE6 proteins (Nomine et al., 2001).
Why do divergent E6 proteins bind acidic LXXLL peptides?
The low risk Alpha genus HPV-11 E6 (11E6) also binds the LXXLL
motif of E6AP (Brimer et al., 2007). Recent studies of BE6 (Delta
genus), HPV-1 E6 (Mu genus) and HPV-8 E6 (Beta genus) reveal that
all three of these E6 proteins bind to the same acidic LXXLL motif of
the MAML1 co-activator (discussed below). Is there some common
underlying biological reason for the interaction of E6 proteins with
acidic LXXLL peptides? Is there some commonality to the acidic
LXXLL of E6AP and the acidic LXXLL of paxillin or MAML1? LXXLL
peptides are used as docking sites for the interaction of nuclear
hormone receptor receptors with their co-activators and co-
repressors (reviewed in Savkur and Burris (2004)). The LXXLL motifs
that associate with nuclear hormone receptors are typically basic
(Heery et al., 1997), while the E6 associated LXXLL motifs are acidic.
Further, while nuclear hormone receptors interact with a 6 amino
acid peptide, E6 proteins interact with an extended 10 amino acid
sequence containing a central LXXLL motif (Fig. 2). The conservation
of acidic LXXLL BE6 binding motifs implies a possibly conserved
biological signiﬁcance that is currently unappreciated (see Table 1 for
a summary of known E6-interacting proteins that contain LXXLL
motifs).
What are the biological consequences of E6 interaction with LXXLL
motifs on cellular proteins?
When E6AP expression is reduced by RNAi in cervical cancer
cell lines, E6 half-life is dramatically reduced (Tomaic et al.,
2009b). Similarly, when 16E6 is expressed in E6AP null cells,Table 1
LXXLL based interactions with Alpha, Beta, or BPV E6s.
Gene name Other name(s) Method Alpha
(low)
Alpha
(high)
Beta
UBE3A E6-AP IP/AP-MS/GPL/
Y2H
+ +
MAML1 MAML1 IP/AP-MS +
PXN Paxillin GST/IP/AP-MS +(92)
AP1G1 AP1 GST/AP/MS
RCN2 E6-BP/ERC-55 GST/IP +
IRF3 IRF3 GST +
TSC2 Tuberin Y2H/GST +
GST: GST pulldown; IP: immunoprecipitation; Y2H: yeast 2-hybrid; GPL: Gaussian prin
that interaction has been noted in the literature. If no “+” the interaction has not been
interaction has been observed/demonsrated. If no number, the interaction has been obs16E6 expression levels are augmented by either co-expression of
E6AP or co-expression of just an LXXLL peptide that binds to 16E6
(Ansari et al., 2012). Thus 16E6 and 18E6 are unstable in vivo in the
absence of binding to a suitable LXXLL peptide. It was further
observed that 16E6 binding to a LXXLL peptide could also restructure
16E6 to interact with p53 in the absence of the entire E6AP protein
(Ansari et al., 2012). Thus, LXXLL peptide interactions stabilize and
restructure 16E6.
For cutaneous type E6 proteins that interact with MAML1, the
transcriptional activation of MAML1 is repressed upon binding to
the E6 protein. It is as yet unknown if these E6 proteins are
restructured upon binding to LXXLL to then interact with addi-
tional cellular proteins as is observed with 16E6 ﬁrst binding to
LXXLL and then recruiting p53 (discussed below).The structure of E6 proteins bound to LXXLL peptides
When expressed in bacteria and concentrated, E6 proteins
become insoluble (Zanier et al., 2007). However, when an LXXLL
peptide from paxillin is fused to the amino-terminus of BE6, the
fused peptide binds to BE6 in cis, blocks transformation by BE6
(Bohl et al., 2000), and solubilizes BE6. 16E6 solubility requires
both provision of the LXXLL peptide of E6AP, mutation of non-
conserved cysteines, and mutation of a dimerization surface in the
amino-terminus of 16E6 to obtain concentrated and soluble
protein preparations (Zanier et al., 2012). These efforts recently
resulted in the crystallization of both BE6 and 16E6 in complex
with LXXLL peptides of paxillin and E6AP respectively (Figs. 3–6;
Zanier et al., 2013).
BE6 and 16E6 contain two zinc-binding domains with a conserved
fold that are connected to each other by a helical linker
Both the amino-terminal E6 zinc-binding domain and the
carboxy-terminal zinc-binding domain have a conserved overall
fold in the crystal to what was previously solved by solution NMR
for the isolated 16E6 C-terminal motif (Nomine et al., 2006; Zanier
et al., 2012). The two zinc domains, together with an alpha-helix
tube that connects them, form a deep pocket into which the LXXLL
peptide makes close contacts (Figs. 3–5). The LXXLL peptides
(MDDLDALLAD from paxillin and ELTLQELLGEE from E6AP) adopt
an amphipathic alpha-helical conformation: the hydrophobic
leucine side chains are oriented to one side and face into the base
of the hydrophobic E6 pocket, opposite from the negatively
charged aspartic and glutamic acids of the LXXLL peptides, which
face out of the pocket and make charge interactions with E6 and
solvent. The alpha helix that connects the N-terminal toBPV References
Brimer et al. (2007), Huibregtse et al. (1991, 1993a), Thomas et al. (2013),
White et al. (2012a)
+ Brimer et al. (2012), Rozenblatt-Rosen et al. (2012), Tan et al. (2012),
White et al. (2012a)
+ Tong and Howley (1997), Vande Pol et al. (1998), White et al. (2012a)
+ Tong et al. (1998)
+ Chen et al. (1998, 1995a)
Ronco et al. (1998)
Lu et al. (2004)
ceps luciferase assay; AP-MS: afﬁnity puriﬁed-mass spectrophotometry. “+” means
published. The number in parenthesis indicates the speciﬁc HPV type in which the
erved/demonstrated in more than one type of the indicated group.
Fig. 4. Ribbon diagram of BE6 bound to an LXXLL motif from paxillin. In the left panel, the amino-terminal zinc-binding domain (green) is shown at the top, the BE6-C
domain in blue, and the helical LXXLL peptide (salmon color) is viewed on end through its axis. The interdomain connecting helix (yellow) is clearly seen in the middle panel,
where the LXXLL peptide has been removed. The right panel is the same view as the middle panel but with the LXXLL peptide residing in the pocket.
Fig. 5. Space ﬁlling views of the 16E6 protein bound to the LXXLL peptide. Colors
and orientation are as in Fig. 3., and the right panel shows the same view but in
space-ﬁlling form.
Fig. 6. Divergent E6 proteins have conserved folds. 16E6 (green) and BE6 (red)
structures are superimposed in the frontal view as shown in Figs. 3 and 4. The
image shows both the extra alpha helix at the amino-terminus of 16E6 compared to
BE6 but also the close conservation of the protein fold. The paxillin and E6AP LXXLL
peptides are colored with their respective E6 proteins. Alignments performed in
PYMOL software.
Fig. 7. Diagram of the functional domains of E6AP. The locations of the nuclear
receptor co-activation region, E6 LXXLL binding domain (aa 409 and another
similar motif at 662) and HECT domain are illustrated. See text for details and
references.
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helix to each of the zinc-binding motifs like a rigid connecting
tube. This interdomain connecting helix also forms part of the
binding pocket for the LXXLL peptide. Speciﬁc contacts between
LXXLL peptide and E6 are discussed in (Zanier et al., 2013).BE6 lacks sequence corresponding to the ﬁrst 14 amino acids of
16E6 that is a conserved feature of both the Alpha and Beta genus
proteins, and within the crystal structure of BE6, the ﬁrst 10 amino
acids of BE6 are not observed, indicating that this sequence had
too much motion to be resolved in the crystal structure (Zanier
et al., 2013). Thereafter, however, the BE6 and 16E6 structural folds
are remarkably similar and superimpose nicely despite the limited
overall sequence conservation (24%) and evolutionary divergence
(Fig. 6; Zanier et al., 2013).
The contacts between the N-terminal and C-terminal zinc
binding domains are not likely strong enough to hold the domains
in the conformation observed in the LXXLL-bound E6 crystal, so E6
could adopt a quite different overall conformation in the absence
of a bound LXXLL peptide. Another way to state this is that LXXLL–
peptide interactions may cause E6 to adopt its ﬁnal conformation.
As noted above, there is evidence in vivo for this, in that 16E6 is
unstable in cervical cancer cells when its preferred binding
partner, E6AP, is not present. However, there is evidence that the
hrE6 proteins have E6AP independent functions; while E6AP is
required for the induction of cervical cancer in mice (Shai et al.,
2010), 16E6 retains oncogenic activity in the skin of E6AP null
mice, indicating an important non-E6AP function for 16E6 or other
associations in skin that stabilize16E6 (Shai et al., 2007).
16E6 contains a dimerization region in the amino-terminal
zinc-binding domain (amino acids 23–24 and 39–47, shown in
purple in the left lower portion of Fig. 3). Lipari et al. (2001) found
that the E6 amino-terminal zinc-binding domain could be
expressed alone in soluble form and dimerized in vitro . This
domain has been delineated by mutagenesis and NMR spectro-
scopy and was shown to be required for the degradation of p53 by
16E6 (Zanier et al., 2012) (discussed below).
At the carboxy-terminus of mucosal hrE6 proteins there is a
short peptide sequence for the interaction with a speciﬁc set of
PDZ domain containing proteins that will be discussed further
below. This peptide motif is unstructured in its unbound state
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crystal structure and NMR structure when bound to MAGI1
(Charbonnier et al., 2011; Zhang et al., 2007).E6* proteins
E6* is an amino-terminal portion of Alpha genus hrE6 protein that
is produced by splicing within the E6 ORF. The splice donor site is
highly conserved, expressing the ﬁrst 42 or 44 amino acids of 16E6 or
18E6 respectively and then a few amino acids of variable non-
conserved sequence derived after the splice acceptors. E6* contains
the ﬁrst CXXC zinc-binding motif of E6. Functions for this polypep-
tide in the context of the complete viral infectious cycle remain
obscure, because mutation of the splice donor site in the context of
the viral genome could alter expression of E7 and E1. E6* is unlikely
to interact with LXXLL. When E6* is expressed as a glutathione S-
transferase (GST) fusion protein, it binds to in vitro translated E6AP,
16E6, 18E6 and inhibited in vitro E6-mediated p53 degradation (Pim
et al., 1997). Similarly, the E6* isoform antagonizes the effect of the
full-length E6 protein upon procaspase 8, stabilizing it rather than
accelerating its degradation (Tungteakkhun et al., 2010). Overexpres-
sion of 18E6* alone promotes proteasome dependent degradation of
a variety of proteins that are the target of full length E6 (such as
DLG1) and additionally alters the expression of proteins that are not
the target of full length E6 (such as AKT) (Pim et al., 2009).
Retrovirally transduced 16E6* and 18E6* target the degradation of
the TIP60 acetyltransferase in keratinocytes (Jha et al., 2010). The
mechanism behind these observations remains obscure, and as yet
no direct and validated cellular interaction targets of E6* are
described. E6* has not been described in the low risk Alpha HPVs,
but a cDNA from BPV-1 encodes a BE6–BE7 fusion protein that has
not been characterized (Yang et al., 1985).What are the main cellular targets of E6 that interact through
LXXLL binding?
Because E6 proteins are expressed at very low levels, identiﬁ-
cation of E6-associated cellular proteins in the past relied upon
overexpression of tagged E6 with immune-puriﬁcation of com-
plexes, yeast two-hybrid screens, and in vitro binding assays.
Although many proteins have been thus identiﬁed, some doubts
have persisted as to the validity of some. As the sensitivity of mass
spectrometry has improved, it has become possible to immuno-
purify epitope-tagged E6 proteins stably expressed in keratino-
cytes and identify associated proteins by mass spectrometry. This
has identiﬁed new interactors and conﬁrmed some previously
identiﬁed interactors.
The most intriguing result of these recent studies is an
apparent dichotomy between those HPVs that replicate in cuta-
neous compared to squamous mucosal epithelia. For papilloma-
virus types that replicate in skin, the E6 proteins examined so far
interact with LXXLL motifs found in MAML family transcriptional
co-activators; for HPV types that replicate in squamous mucosa
(Alpha types), their E6 proteins associate with the LXXLL motif in
E6AP (Brimer et al., 2012; Rozenblatt-Rosen et al., 2012; Tan et al.,
2012; White et al., 2012a). Although dual recognition can be
observed in overexpression, in vitro binding, or yeast two-hybrids,
there is not yet compelling evidence that E6 proteins associate at
normal expression levels with both MAML1 and E6AP in vivo. The
converse result also holds: while Alpha group E6 proteins interact
with E6AP, they do not interact with MAML1, and while Beta group
E6 proteins interact with MAML1 they interact poorly with E6AP
(Brimer et al., 2012; White et al., 2012a). Further examination of
other genus and animal papillomaviruses will determine if this isdue to mucosal versus cutaneous biology or reﬂects an early
evolutionary divergence in replication strategy.
Other experimental approaches come to somewhat different
conclusions about cellular E6 interactors as is seen in the compar-
ison of E6 interactors that are identiﬁed by yeast 2-hybrid screens
and those identiﬁed by IP/MS. Two recent high-throughput
analysis of multiple cutaneous and mucosal E6 types identiﬁed
largely non-overlapping sets of interacting proteins compared to
those identiﬁed by IP/MS (Neveu et al., 2012; Rozenblatt-Rosen
et al., 2012), despite the further validation in one of those studies
of the interactions by mammalian high-throughput protein com-
plementation assay (based on Gaussia princeps luciferase, GPL
methodology; Neveu et al., 2012). Although some targets are
common to both data sets, most are not; there is currently a lack
of consensus on how to interpret these disparate results.
A critical tool in the analysis of both E6 interactors and E6
biological effects are mutations in E6. Until the structure of E6 was
solved, it was difﬁcult to discern if E6 mutants were selectively
defective for a particular function, such as LXXLL peptide binding,
or were globally defective because the mutation disrupted the
E6 protein fold. For most mutants, this type of analysis has not
been performed. Since E6 interaction with LXXLL peptides requires
proper folding for most of the E6 sequence, truncation or in-frame
deletion mutants of E6 are for the most part untrustworthy, and
will not be considered further here. An exception is the linear PDZ
binding motif at the carboxy-terminus of E6, which can be deleted
without compromising the E6 pocket. Table 5 is a compilation of
16E6 point mutants with associated phenotypes.
Alpha group E6 proteins associate with E6AP
As mentioned above, hrE6 proteins associate with E6AP illu-
strated in Fig. 7 (Huibregtse et al., 1993a). It was determined that
this leads to the recruitment of p53 and the transfer of ubiquitin
from a thioester cysteine bond in the E6AP ubiquitination domain
to p53 (Scheffner et al., 1993). Although rabbit reticulocyte lysate
supported the degradation of p53, wheat germ lysate did not
unless supplemented with E6AP. The carboxy-terminal ubiquitina-
tion domain was found present in a family of similar ubiquitin
ligases now termed HECT domain ubiquitin ligases (for Homo-
logous to E6AP Carboxy-Terminus) of which E6AP is the prototype
(Huibregtse et al., 1995). Mutation of the cysteine that conjugates
with ubiquitin creates a dominant negative form of E6AP that can
bind to E6 and p53 but fails to result in p53 degradation. E6AP
expression is imprinted, and loss of E6AP or mutation with loss
of ubiquitin ligase activity is the cause of Angleman syndrome, a
complex neuro-developmental disorder (Kishino et al., 1997;
Matsuura et al., 1997). How loss of E6AP ubiquitin ligase activity
results in the Angelman syndrome remains poorly understood.
Expression of 16E6 from the Keratin 14 promoter (K14-16E6) in
mice produces skin hyperplasias and cervical cancers with pro-
longed latency when the mice are also treated with estrogen; in
this system, estrogen induces cervical and vaginal neoplasms that
is enhanced by K14-16E6; deletion of E6AP ablated this enhance-
ment (Shai et al., 2010). K14-16E6 mice null for E6AP have
enhanced incidence of cancer compared to estrogen treated
animals without E6 (Shai et al., 2010). Cell cycle arrest in K14-
16E6 irradiated mouse skin is ablated by E6, but surprisingly this
phenotype did not require E6AP, demonstrating that 16E6 can
ablate p53 function without E6AP despite the increase of p53
expression in K14–16E6–E6AP−/− mice compared to K14-16E6
mice (Shai et al., 2010). 16E6 has been reported to target p53
degradation in E6AP null mouse cells by an unknown mechanism,
but another group has not observed E6AP independent p53
degradation in the same cells (Ansari et al., 2012; Massimi et al.,
2008).
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mice that express hrE6 and hrE7. In 1999, Nawaz et al. demonstrated
that E6AP could serve as a co-activator for estrogen, gluccocorticoid,
androgen, thyroid hormone and retinoic acid receptors in transient
transfection assays. E6AP is recruited to the androgen-responsive PSA
promoter (Khan et al., 2006), and to the estrogen-responsive pS2
promoter in a hormone responsive manner (Reid et al., 2003). E6AP
was shown to be able to target the degradation of the estrogen
receptor and progesterone receptor (Li et al., 2006). The role of E6AP
as a nuclear receptor co-activator has been recently reviewed
(Ramamoorthy and Nawaz, 2008).
E6AP associates with a second ubiquitin ligase, HERC2, that is
isolated in association with high and low risk E6 proteins in a high
molecular weight nuclear complex (Martinez-Noel et al., 2012;
Rozenblatt-Rosen et al., 2012; Vos et al., 2009; White et al., 2012a).
HERC2 is a HECT domain ubiquitin ligase that through association
with E6AP can stimulate the ubiquitin ligase activity of E6AP and
may thus regulate E6AP activity (Kuhnle et al., 2011).
Early in vitro binding assays showed enhanced avidity of
bacterially expressed GST-16E6 for E6AP compared to GST-18E6,
GST-11E6 or GST-6E6 (Huibregtse et al., 1993a), but the compara-
tive in vivo afﬁnities of different alpha E6 proteins for E6AP and
what consequences such afﬁnity differences could confer in vivo is
unknown. Low risk Alpha group E6 proteins, such as HPV types
6 or 11, interact with E6AP in vivo and activate E6AP ubiquitin
ligase activity, yet have not been found to target the degradation of
p53 (Brimer et al., 2007). E6AP is also found in association with
low-risk E6 types in IP/MS experiments (Rozenblatt-Rosen et al.,
2012; White et al., 2012a). Substrates for the low risk Alpha HPV
E6 proteins that are analogous to p53 for the hrE6 proteins have
not yet been identiﬁed.Secondary substrates of Alpha group E6 proteins that associate with
E6AP: p53
How does p53 associate with the E6–E6AP complex? As noted
above, the association of E6 with E6AP (Scheffner et al., 1993), or
even a peptide similar to the LXXLL of E6AP (Ansari et al., 2012)
alone is sufﬁcient to restructure 16E6 to interact with p53 in yeast
hybrid analysis. Many mutations made in E6 ablate the ability of
E6 to interact with LXXLL, and thus also ablate the interaction with
p53. However, mutations in the very amino-terminus of E6 and
others elsewhere in the N-terminal zinc domain retain the
capacity to interact with E6AP, yet lose the capacity to interact
with p53 or target the degradation of p53 (Cooper et al., 2003; Kao
et al., 2000; Liu et al., 1999).
The interaction of 16E6 with E6AP induces the dimerization and
ubiquitination of E6AP (Nuber et al., 1998). 16E6 mutations of the
dimerization surface disrupt both E6 dimerization and p53 in vitro
degradation; thus, the dimerization of E6 is functionally linked to the
initiation of degradation of p53 (Zanier et al., 2012). When a mutant
in the dimerization domain was expressed in HeLa cells (an HPV-18
high risk E6 expressing cell line) it induced senescence, presumably
through a dominant negative interaction with E6AP and p53
(Ristriani et al., 2009). The E6–E6AP–p53 complex requires the ability
of E6 to multimerize via self-association of the amino-terminal
domain of E6 (Zanier et al., 2012) in order to initiate the transfer of
ubiquitin from a carboxy-terminal thioester in the HECT domain of
E6AP to p53 (Scheffner et al., 1993).
In vitro and yeast expression binding experiments have shown
that E6+E6AP or E6+LXXLL peptide associates with the core DNA
binding domain of p53 when p53 is in a native conformation, but
does not associate with the DNA binding domain of most (but not
all) p53 cancer associated mutants (Ansari et al., 2012; Scheffner
et al., 1992). A second modality of E6 association with p53 was
deﬁned using bacterially expressed E6 proteins; GST-E6 proteinfrom both high and low risk papillomavirus types associate in vitro
with the p53 oligomerization domain at the carboxy-terminus of
p53 (Li and Cofﬁno, 1996). It remains controversial if this is a
biologically meaningful result or an artifact of bacterially
expressed and detergent treated E6.
The fact that the interaction of 16E6 with E6AP induces the
dimerization and ubiquitination of E6AP may explain the observa-
tion that E6AP expression and half-life are reduced in cervical
cancer cell lines (Kao et al., 2000). In contrast, in K14–16E6
transgenic mice there is no reduction of E6AP in tissues expressing
E6 compared to non-E6 expressing cells (Shai et al., 2010). A
related question is how does E6 escape being the target of E6AP
ubiquitination and degradation? E6 immunopuriﬁed from cell
lysates is in a complex with the ubiquitin speciﬁc protease
USP15 (Vos et al., 2009). RNAi knockdown of USP15 resulted in
the reduction of E6 expression but there was no induction of p53
in cervical cancer cell lines, indicating that further development of
this area is an important research goal.
While hrE6 targets p53 degradation, residual p53 often
remains, yet checkpoint control and p53-induced apoptosis is
blocked. Low risk E6, and Beta-papillomavirus E6 (both of which
fail to target p53 degradation) block some p53-induced transcrip-
tion (Giampieri et al., 2004); one important mechanism involves
modulation of protein acetylation (discussed below). HrE6 degra-
dation of p53 is blocked by inhibitors of nuclear export indicating
that p53 degradation occurs in cytoplasmic and not nuclear
proteasomes (Freedman and Levine, 1998; Hietanen et al., 2000;
Stewart et al., 2005).
Because hrE6 proteins target the degradation of p53, other E6
proteins have been examined for the same property without
success. However, it is premature to dismiss roles of low-risk E6
in manipulating p53 because degradation has yet to be observed.
Low risk Alpha E6 proteins are reported to block the activation of
p53 by blocking the acetylation of p53 (Thomas and Chiang, 2005),
and to block the transcriptional induction of pro-apoptotic genes
after DNA damage (Giampieri et al., 2004). Interestingly, p53 co-
immunoprecipitates with HPV-38 and HPV-92 E6, and these two
E6 proteins as well as additional Beta genus E6 types stabilize p53
in vivo (White et al., 2012a); HPV-38 E6 and E7 together induce
deltaNp73 which acts as a repressor of p53 function resulting in
the loss of UV checkpoint control (Accardi et al., 2006; Dong et al.,
2008). Since these E6 proteins associate with MAML1 and not
E6AP, the role of these p53 associations is as yet unknown.
Other secondary substrates of the high risk E6+E6AP complex
identiﬁed by IP/mass spectrometry
Proteasome subunits have been found in association with high and
low risk Alpha type E6 proteins in two studies utilizing immune
precipitation and mass spectrometry (Rozenblatt-Rosen et al., 2012;
White et al., 2012a). In both studies, 16E6 mutant I128T, which
reduces E6AP association with E6, also greatly reduced proteasome
association with E6, suggesting that proteasome subunits associate
with E6 through association with E6AP, which has been previously
described (Besche et al., 2009; Wang et al., 2007).
P300/CBP
Alone among the Alpha group E6 proteins, HPV16 E6 associated
with CBP/p300 in a IP/MS experiment (White et al., 2012a) which
was in agreement with earlier studies that identiﬁed p300 by
hypothesis-directed in vitro binding and that proposed to thereby
effect NfkB and p53 transactivation (Patel et al., 1999; Zimmermann
et al., 1999; Thomas and Chiang, 2005). The mechanism of 16E6
association with p300 is as yet unresolved; it could be a direct
association or it could depend upon prior association with E6AP
and/or p53.
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The cellular E6TP1 protein (SIPA1L1 gene product) was isolated
by yeast two-hybrid, and is a Ran-Gap protein with a PDZ domain
that is targeted by high risk E6+E6AP for degradation, although
not through PDZ-mediated association with E6 (Gao et al., 2002,
1999). E6TP1 has not been identiﬁed in IP/MS experiments
associated with E6, but was a common target of cutaneous andTable 2
Secondary E6 interactors.
Gene name Other name (s) Method Alpha
(low)
Alpha
(high)
Beta
BAK1 Bak GST/HA + + +
BARD1 BARD1 Y2H/FL +
BRCA1 Brca-1 GST/GPL +
CASP8 Procaspase 8 HA/FL
CREBBP CBP GST/FL/HA/AP-MS +(16) +
CYLD CYLD1 HA +(16)
EP300 P300 GST/FL/HA/AP-MS + +(16) +
FADD FADD GST/GPL + +
GPS2 Gps2 Y2H/GST/IP + +
HERC2 SHEP1 TAP-MS/AP-MS + +
KAT5 Tip60 GST + +
MCM7 Mcm7 Y2G/MBP + +
MGMT MGMT IP + +
MYC c-Myc IP +(16)
NFX1 NFX1-91 Y2H/IP +(16)
PML PML GST + +(18)
NOTCH1 NOTCH1 AP-MS +(so
NOTCH2 NOTCH2 AP-MS +(so
SIPAIL1 E6TP1 Y2H/GST/GPL +
SLC12A8 CCC9 AP-MS + +(92
TADA3 Ada3 Y2H/IP/GPL + +
TERT TERT GST/AU1-IP +(16)
TNFRSF1A TNF R1 Y2H/HA-IP
TP53 P53 GST/IP/AP-MS + + +(38
TYK2 Tyk2 GST/FL +(18)
USP15 USP15 AP-MS +(16)
XRCC1 XRCC1 Y2H/IP + +
ZYX Zyxin Y2H/GST/MY +(6)
HPV-17a and 38
AMBRA1 DCAF AP-MS +
MX2 MXB AP-MS +
NEK1 SRPS2 AP-MS +
UHMK1 KIST AP-MS +
MTA1 MTA1 AP-MS +
UBR4 P600 AP-MS/GST +
KCMF1 DEBT91 AP-MS +
TNKS1BP1 Table182 AP-MS +
C2orf29 C2orf29 AP-MS +
CNOT1-10 Ccr-Not AP-MS +
C21orf2 YF5/A2 AP-MS +(17
UBA5 UBE1DC1 AP-MS +(17
UFM1 UFM1 AP-MS +(17
JMJD1C TRIP8 AP-MS +(17
TANK1 PARP5A AP-MS +(17
TJAP1 PILT AP-MS +(17
HPV-92 speciﬁc
AAMP AAMP AP-MS + (9
ARNT HIF1β AP-MS + (9
AZI1 CEB131 AP-MS + (9
CAMSAP3 NEZHA AP-MS + (9
CEP152 CEP152 AP-MS + (9
CEP44 KIAA1712 AP-MS + (9
CEP63 CEP63 AP-MS +(92
DUSP3 DUSP3 AP-MS +(92
HIF1A HIF1α AP-MS +(92
JUB JUB AP-MS +(92
SLC12A8 CCC9 AP-MS + +(92
GST: GST pulldown; HA: HA tag pulldown; MY: myc tag pulldown; FL: ﬂag tag pulldown
GPL: Gaussian princeps luciferase assay; AP-MS: afﬁnity puriﬁed-mass spectrophotome
been noted in the literature. If no “+” the interaction has not been published. The numb
observed/demonsrated. If no number, the interaction has been observed/demonstratedmucosal types in yeast hybrid and mammalian GPL interaction
analysis (Neveu et al., 2012). Tuberin has been reported as targeted
for degradation by high risk E6 but also in a later report as a target
of E6AP in the absence of E6 (Lu et al., 2004; Zheng et al., 2008);
one other study that examined tuberin did not see enhanced
degradation of tuberin within E6 expressing keratinocytes
(Spangle and Munger, 2010). NFX-91 was isolated as an E6+E6APBPV References
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targeted for degradation by 16E6 and to be a regulator of
telomerase expression (see subsequent discussion of telomerase;
Gewin et al., 2004). Additional secondary targets of E6 proteins are
listed in Table 2.
Beta, Delta and Mu genus cutaneous E6 proteins associate with
MAML family proteins
In contrast to the Alpha genus E6 proteins that interact with
E6AP, BE6 and HPV E6 proteins from the Beta and Mu Genus
associate with MAML1 (BPV and HPVs) and MAML3 (BPV-1 E6),
binding a LXXLL motif near the carboxy-terminus of MAML and
repressing the activity of the Notch transcriptional activation
complex as will be discussed below (Fig. 2) (Brimer et al., 2012;
Rozenblatt-Rosen et al., 2012; Tan et al., 2012; White et al., 2012a).
As would be expected, the subunits of the Notch transcription
complex (RBP-J and Notch1) were also detected with MAML1 in
association with these E6 proteins. Additional proteins were found
in association with the Beta genus E6 proteins, but restricted to
species within the genus and it is unclear if these associations are
direct with E6 or dependent upon the prior binding of E6 to a
LXXLL protein, presumably MAML1. The CCR4–Not complex was
found in association with Beta-species 2 (HPV-92), associated with
HIF1α/HIF1β and centrosome localized proteins. Beta genus spe-
cies 1 (HPV-8 prototype) have strong association with CBP/p300
(Howie et al., 2011; Rozenblatt-Rosen et al., 2012; White et al.,
2012a). P300/CBP have LXXLL docking sites and could serve as a
primary docking site via LXXLL interactions, but this has not yet
been demonstrated and those sites do not closely resemble the
LXXLL sites of E6AP, MAML1, and paxillin. Interestingly, UBR4, a
large ubiquitin ligase that participates in the N-end rule protein
degradation pathway and is a primary binding protein of HPV E7
oncoproteins (Demasi et al., 2005; Huh et al., 2005; White et al.,
2012b), was found to associate with 17E6 and 38E6 (Thomas et al.,
2013; White et al., 2012a).
BE6 associates with multiple cellular binding proteins via LXXLL
interactions
BE6 was found to associate with paxillin by IP/MS in transiently
transfected cells (Tong and Howley, 1997), and yeast two-hybrid
(Vande Pol et al., 1998). BE6 binds to a LXXLL motif similar to that
of E6AP (Fig. 2), and BE6 mutants that discriminate in binding
between E6AP and paxillin suggested that BE6 transformation was
more closely related to paxillin association than E6AP (Das et al.,
2000). Paxillin knockout cells are not transformed by BE6 unless
reconstituted with paxillin, indicating that paxillin is required for
BE6 transformation or alternatively that paxillin might be gener-
ally required for anchorage independent cell proliferation (Wade
et al., 2008). BE6 also associates with the AP1 adaptor complex for
clathrin endocytosis (Tong et al., 1998); that association was not
clearly linked to transformation by BE6. As discussed above, BE6 is
associated with MAML1 and MAML3 and represses notch signal
transduction, but dominant negative MAML1 does not transform
cells that are transformed by BE6 (Brimer et al., 2012). It may be
that multiple interactions by BE6 with LXXLL motifs on multiple
proteins are required for full transformation by BE6.After binding to LXXLL, how does E6 interact with secondary
associated proteins?
Binding experiments in vitro and in yeast demonstrated that the
ﬁrst 8 amino acids of 16E6 could be deleted, ablating p53 binding but
without ablating E6AP association (Kao et al., 2000, #663); thus,while a central core region of E6 (corresponding to BE6 amino acids
11–132) is required for LXXLL interactions, additional amino-terminal
sequences seem to be for other interactions. Much work remains to
understand these interactions, since in only a single instance (cancer
associated HPV E6 and its p53 interaction) have any such interactions
been demonstrated and mapped to the amino-terminal surface of E6
(Cooper et al., 2003).
In the case of BE6, there are 10 amino acids that must be deleted
before the ability of BE6 to bind to LXXLL motifs is abolished. For
most papillomaviruses, the amount of “extra” amino-terminal
sequences beyond that required to interact with LXXLL peptides is
more substantial than BE6, ranging from 23–25 amino acids for the
cancer associated E6 proteins, to 34 amino acids for the cutaneous
HPV-5 E6, and an entire additional zinc-binding domain for the long
form of CRPV E6 (Meyers et al., 1992). These amino-terminal
sequences are candidates for secondary E6 associated proteins.
The crystal structure of LXXLL-bound 16E6 reveals numerous
clefts and surfaces that could mediate other protein-protein
interactions. Unfortunately, 16E6 deletion mutants typically used
to delineate binding sites are predicted to ablate the overall fold of
16E6, making such mutants undesirable to map protein-protein
interactions, and most 16E6 point mutants have not been well
enough characterized for LXXLL interactions, stability, and reten-
tion of secondary function to inspire conﬁdence. The recent
structure should allow a new generation of mutants to be
characterized for the mapping of biological functions and associa-
tions on the surface of E6.A PDZ ligand on hrE6 interacts with cellular PDZ containing
proteins implicated in signal transduction and polarity
PDZ domains (named for the proteins PSD95, DLG, and ZO1) are
small domains that bind to peptide ligands on target proteins. PDZ
peptide ligands can be internal, but are most typically carboxy-
terminal peptide ligands with a consensus sequence XX(S/T/Y)X
(V/L/M). Adapter proteins often contain multiple PDZ domains,
resulting in large complexes built through the association of
multiple PDZ domain proteins and their binding partners. Afﬁ-
nities of PDZ-ligand interaction are typically in the low micro-
molar range, and can be modulated by phosphorylation of the PDZ
ligand or the PDZ domain (reviewed in Lee and Zheng (2010)).
DNA tumor viruses that target p105RB by viral oncoproteins such
as Adenovirus E1A, SV40 TAg, or high risk HPV E7 also produce
proteins that either associate with cellular proteins containing PDZ
domains, or target cell polarity (reviewed in Javier (2008) and Tomaic
et al. (2009a)). For example, Adenovirus E1A interacts with RB, and
the E4ORF4 protein associates with cellular PDZ proteins. High risk
papillomavirus E7 targets RB for degradation and hrE6 associates
with a subset of PDZ proteins via an 8 amino acid PDZ ligand at its
carboxy-terminus. Different hrE6 proteins vary in the sequence of the
PDZ ligand and consequently target somewhat different sets of PDZ
domain proteins (Thomas et al., 2005). Similar to the high risk HPVs,
SV40 TAg associates with RB and small t antigen disrupts the
integrity of cellular tight junctions (Nunbhakdi-Craig et al., 2003).
In contrast to hrE6, Low-risk Alpha E6 proteins do not have a
carboxy-terminal PDZ ligand, nor do Beta genus or BE6. Interestingly,
the rhesus monkey papillomavirus E7 protein both targets RB and
has a PDZ ligand at the carboxy-terminus that can interact with
scribble and PAR3, PDZ binding proteins that also complex with hrE6
(Tomaic et al., 2009a).
The PDZ ligand of 16E6 alters differentiation of the skin or eye
in transgenic mice (Nguyen et al., 2003a; Nguyen et al., 2003b;
Simonson et al., 2005. Under low expression conditions, the PDZ
ligand of E6 reduces growth factor dependence in human kerati-
nocytes (Jing et al., 2007). In SV40 immortalized keratinocytes, the
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(Watson et al., 2003), and in human keratinocytes the E6 PDZ
ligand promotes co-operation with ras and anchorage indepen-
dent colony formation (Spanos et al., 2008a). In the context of the
entire hrHPV genome, deletion of the E6 PDZ ligand causes loss of
the viral plasmid upon cell passaging (Lee and Laimins, 2004).
So which PDZ associations with E6 mediate these phenotypes?
Described interactions are shown in Table 3. Although there are
hundreds of cellular proteins with PDZ domains only a handful
associate with high risk E6 proteins through PDZ interactions. It is
as yet unclear if one or more than one of these interactions is
critical for the virus life cycle or cancer. All of these associations
were published as resulting in the targeted degradation of the PDZ
protein, usually in an E6AP and proteasome dependent manner,
analogous to the previously described and widely replicated
targeted degradation of p53 by high risk E6 proteins. Like p53,
such degradation is supported in vitro from reticulocyte-translated
proteins. However, the targeted overall degradation of some of the
PDZ proteins by E6 in vivo has been challenged (Kranjec and
Banks, 2010). DLG1, which is targeted for degradation by hrE6
in vitro, does not show reduced expression or re-localization in the
context of E6 expressed from episomal genomes in primary
keratinocytes (Lee and Laimins, 2004). Some studies have found
that only certain subcellular fractions of hrE6-associated PDZ
proteins are degraded (Massimi et al., 2004, 2006; Narayan et al.,
2009) but again, these experiments involve expression levels
presumably higher than produced by episomal genomes. While
multiple PDZ domain proteins have been described after afﬁnity
isolation or yeast two-hybrid identiﬁcation, only scribble, PDZ11
and the tyrosine phosphatases PTPN3 and PTPN13 were isolated
by IP/MS of E6 in stably expressing keratinocytes (White et al.,
2012a). Interestingly, PDZ11 and PTPN13 were also associated with
some Beta genus E6 proteins even though they do not have a
classic carboxy-terminal PDZ binding motif (White et al., 2012a).
Adding further complication, the E6* protein (produced by internal
splicing of high risk E6 proteins) reduces the half-life of DLG1 and
other PDZ proteins despite having no PDZ ligand with which to
associate with PDZ proteins (Pim et al., 2009).
Studies as to the mechanism by which E6 may reduce expression
of PDZ proteins, have differed with most showing E6AP dependence
(Handa et al., 2007; Jing et al., 2007; Kuballa et al., 2007), but others
observing neither ubiquitin nor proteasome dependence (Ainsworth
et al., 2008; Grm and Banks, 2004). The E6 PDZ ligand can be
phosphorylated (Massimi et al., 2001), resulting in association of E6
with 14-3-3 proteins to the exclusion of PDZ proteins (Boon andTable 3
PDZ interactors with high-risk E6s.
Gene name Other name (s) Method Comments on protein
DLG1 hDlg GST/MY MAGUK cell polarity/junction p
GOPC CAL GST/MT/HA/MS Vessicular trafﬁcking
INADL PATJ Y2H/GST/FL/MY Tight junction associated
MAGI1 MAGI-1 GST/HA/GPL MAGUK cell polarity/junction p
MAGI2 MAGI-2 GST MAGUK cell polarity/junction p
MAGI3 MAGI-3 GST MAGUK cell polarity/junction p
MUPP1 MUPP1 GST MAGUK cell polarity/junction p
PTPN13 PTPN13 IP Phosphatase; degradation invol
independent growth and invasi
potentiates MAP kinase signalin
PTPN3 PTPN3 IP/TAP Phosphatase; degradation redu
requirements
SCRIB Scribbled IP/GPL/MS MAGUK cell polarity/junction p
YWHAC 14-3-3zeta GST/HA Contributes to steady-state leve
phosphorylation by PKA
GST: GST pulldown; HA: HA tag pulldown; MY: myc tag pulldown; FL: ﬂag tag pulldown
GPL: Gaussian princeps luciferase assay; MS: mass spectrophotometry; MT: Maldi-Tof.Banks, 2013). Thus, particular culture conditions in vivo for PDZ
interactions with E6 may be necessary for modulation of phosphor-
ylation to occur before phenotypes are observed, which could
account for some discordant observations in the literature.
The crystal structure of the PDZ domains of DLG1 and MAGI1 in
association with the PDZ ligand of E6 has been solved (Zhang et al.,
2007), as has the solution structure of the second PDZ domain of
MAGI1 in the presence and absence of the E6 PDZ ligand
(Charbonnier et al., 2011).Biological functions of E6
The previous sections focused mainly on E6 structure and the
mechanisms by which different E6's interact with cellular proteins. A
wealth of information exists on how E6 and E7 affect various aspects
of transformation, cell differentiation, metabolism, immune response,
and virus replication. Some of these topics have already been
touched upon earlier in this review because they ﬁt well with the
discussion on E6-interacting proteins. Here, we will discuss other
topics in more detail to convey a wider appreciation of the biological
functions that have been attributed to E6. Many of these functions
have been discovered through studies of E6 proteins from mucosal
alpha HPV types that are associated with human disease (Table 4).
Where appropriate, we will also discuss E6 functions that have been
attributed to cutaneous beta types.
Transformation and immortalization
It should be emphasized that E6 and E7 are expressed together
in HPV infected and transformed cells. There is value, however, in
dissecting the functions of E6 and E7 by expressing them indivi-
dually. As mentioned in the introduction, early studies focused on
the ability of hr-HPV to transform 3T3 cells (Yasumoto et al., 1986)
and then E6 and E7 to transform rodent cells and immortalize
human keratinocytes (Bedell et al., 1989; Durst et al., 1987; Phelps
et al., 1988; Pirisi et al., 1987; Sedman et al., 1991; Storey et al.,
1988). HrE6 is effective in combination with oncogenic Ras in
transforming baby rat kidney (BRK) cells; mutants of hrE6 that
were unable to cause the degradation of p53 still had some
transforming potential, indicating p53 independent functions
(Pim et al., 1994; Storey and Banks, 1993). HPVs infect keratino-
cytes, and ideally, examination of how the different proteins affect
function should be done in this type of cell. Full-length E6 from
high-risk types such as 16, 18, and 31 can extend the lifespan ofReferences
rotein Gardiol et al. (1999), Kiyono et al. (1997),
Massimi et al. (2004)
Jeong et al. (2006), White et al. (2012b)
Latorre et al. (2005), Storrs and Silverstein (2007)
rotein Glaunsinger et al. (2000), Neveu et al. (2012)
rotein Thomas et al. (2002)
rotein Thomas et al. (2002)
rotein Lee et al. (2000)
ved in anchorage
ve properties;
g
Hoover et al. (2009), Lee et al. (2000),
Spanos et al. (2008b)
ces growth factor Jing et al. (2007)
rotein Nakagawa and Huibregtse (2000), White et al. (2012a)
ls of E6 by regulating Boon and Banks (2013)
; IP: immunoprecipitation; Y2H: yeast 2-hybrid; TAP: tandem afﬁnity puriﬁcation;
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efﬁcient immortalization frequency (Hawley-Nelson et al., 1989;
Hudson et al., 1990; Munger et al., 1989; Sedman et al., 1991;
Woodworth et al., 1989). A caveat to this is that hrE6 can
immortalize epithelial cells (e.g. mammary epithelial cells) that
have an aberrant RB pathway (through down regulation of the
cdk/cyclin inhibitor p16) (Band et al., 1991; Dalal et al., 1996; Foster
et al., 1998). Low-risk mucosal E6s have little transformation
function in keratinocytes (Band et al., 1993; Halbert et al., 1992).
Of the cutaneous Beta HPVs only a subset are able to transform
primary human keratinocytes. Expression of E6/E7 in combination
from HPV-5,-8, -24, -36, and -38 extends the lifespan of human
keratinocytes (Bedard et al., 2008) with occasional subpopulations
of cells emerging that are immortal, particularly in HPV-38 and 49
E6/E7 cultures (Bedard et al., 2008; Cornet et al., 2012). Immorta-
lization by CRPV and HPV-38 E6 involves the inhibition of p53
dependent apoptosis via the association of E6 with p300 and
blocking the acetylation of p53 (Muench et al., 2010).
As discussed in previous sections, transgenic mice that express
high risk E6 and E7 develop cancer (Lambert et al., 1993), a phenotype
that is primarily due to E7 expression (Riley et al., 2003), but
high-risk mucosal HPV-16 E6 has modest transforming functions
when expressed as a transgene from a keratin speciﬁc promoter
in the epithelium of mice; this activity was lost upon deletion of
the PDZ domain of E6 or mutation of I128T which greatly
decreases E6AP association with 16E6 (Nguyen et al., 2002,
2003a; Riley et al., 2003; Simonson et al., 2005; Song et al., 1999).
The vast sequencing of HPV-16 genomes has shown associa-
tions between certain polymorphisms within E6 (particularly
L86V) and the relative risk of developing cancer, but the reasons
for this remain poorly understood (Cornet et al., 2013).
E6 and telomerase
E6s from high-risk mucosal HPVs and from certain cutaneous HPVs
are capable of activating telomerase, the enzyme complex that adds
telomere repeats to the ends of chromosomes (Klingelhutz et al.,
1996). The activation of telomerase was found not to be dependent on
the ability of E6 to target p53 for degradation since the 16E6-8S9A10T
mutant could still activate telomerase but not degrade p53 and
conversely, the Δ118–122 mutant that has partial ability to target
p53 could not activate telomerase (Kiyono et al., 1997; Klingelhutz
et al., 1996). Most studies indicate that E6s activate telomerase through
transcriptional up regulation of TERT, the reverse transcriptase com-
ponent of telomerase (Gewin and Galloway, 2001; Oh et al., 2001;
Veldman et al., 2001). A recent study demonstrated that there was a
strong correlation between the ability of E6 of certain HPV types to
activate the TERT promoter and the association of those types with
cancer (Van Doorslaer and Burk, 2012). The mechanism by which this
occurs is not entirely clear but appears to involve E6AP binding (Gewin
and Galloway, 2001; Oh et al., 2001). The 16E6 L50G mutant is
defective in binding E6AP and does not activate telomerase, and
knockdown of E6AP by shRNA abrogates the ability of 16E6 to up
regulate TERT (Gewin et al., 2004). The PDZ binding domain of 16E6 is
dispensible for telomerase activation (Klingelhutz et al., 1996). One
model proposes that E6 and E6AP bind to a repressor of TERT
transcription called NFX1-91 which binds to the mSin3a/HDAC com-
plex that causes deacetylation of histones (Gewin et al., 2004;
Katzenellenbogen et al., 2009; Xu et al., 2008). Interaction with E6
causes the ubiquitination of NFX1-91, degradation, and release of
transcriptional repression at the TERT promoter. The NFX1 locus also
codes for a splice variant called NFX1-123 which apparently stabilizes
TERT transcripts in HPV-16 E6 expressing cells by binding to poly-
(A) binding proteins (Katzenellenbogen et al., 2007, 2009). Another
model indicates that E6 and E6AP bind to c-myc and that this
somehow causes c-myc to be a better transcriptional activator ofTERT (Veldman et al., 2003). Mutations of the E box in the TERT
promoter affects the ability of E6 to activate TERT in experiments
using TERT-promoter luciferase constructs (Au Yeung et al., 2011;
James et al., 2006a; Veldman et al., 2003). In the context of E6
expression, the c-myc protein may displace the inhibitory USF
transcriptional repressor from the E box in the TERT promoter
(McMurray and McCance, 2003). These two models are not mutually
exclusive and other mechanisms are possible. Interestingly, hrE6 has
been shown to bind directly to the TERT protein but the conse-
quences of this in telomerase activation are not entirely clear (Liu
et al., 2009). The observation that Beta HPV types, such as HPV-5
and HPV-8 that are associated with skin cancer, can also activate
telomerase brings an added complication (Bedard et al., 2008).
Although it has been shown that the Beta E6 proteins can associate
with E6AP in vitro and in transient expression assays (Thomas et al.,
2013), in stable expression IP/MS experiments, E6AP binding was
not observed (White et al., 2012a). Thus, the mechanism of telomer-
ase activation by the Beta types may be different.
It is clear that different culture conditions (such as culturing in
serum and ﬁbroblasts feeder cells compared to serum-free low
calcium media formulations) affect the induction of telomerase in
keratinocytes, raising the possibility that much of the ultimate effects
of E6 upon telomerase expression could be rather indirect (Fu et al.,
2003). The reason HPV activates telomerase is unknown. It would not
appear to be essential for replication since a large number of types do
not activate telomerase. One possibility is that telomerase activation
allows an extension of keratinocyte lifespan to provide an advantage
for replication. However, immortalization of cells is not necessary for
HPV replication and low-risk types that do not activate telomerase
are certainly able to replicate. Adding to the confusion, telomerase
mutants defective for enzymatic activity immortalize keratinocytes
in combination with hrE7 proteins (Miller et al., 2013). It is possible
that TERT has other functions besides telomere elongation, such as
inhibition of apoptosis, and certain HPVs could be taking advantage
of this to increase replication or cell survival to allow replication
(Saretzki, 2009). A consequence is that infection with these types
provides a higher likelihood of malignant conversion.
P53 regulation by high risk E6
To summarize the material presented so far on how hrE6s
target p53 for degradation, 16E6 is unstable upon translation
in vivo but is stabilized upon binding the LXXLL peptide on E6AP
(Tomaic et al., 2009b), and changes its conformation to one that
interacts with p53 (Ansari et al., 2012). The E6–E6AP–p53 complex
requires the ability E6 to multimerize via self-association of the
amino-terminal domain of E6 (Zanier et al., 2012) to initiate the
transfer of ubiquitin from a carboxy-terminal thioester in the HECT
domain of E6AP to p53 (Scheffner et al., 1993). This then leads to
the degradation of p53 through the proteasome.
Effects of E6 on transcription
p53-dependent and p53-independent alterations of global
cellular transcription by hrE6 proteins has been observed in
transduced keratinocytes (Duffy et al., 2003; Garner-Hamrick
et al., 2004; Kuner et al., 2007; Mendoza-Villanueva et al., 2008).
E6 effects upon cellular signal transduction by hrE6 could in part
explain these effects (such as through the effects of E6 upon
cellular PDZ proteins), however, several speciﬁc interactions of E6
with cellular transcription complexes is the likely cause. Histone
acetyltransferases (HATs) are components of eukaryotic transcrip-
tion complexes. Apart from acetylating histones to enable chro-
mosomal remodeling, several HATs (p300, CBP, PCAF, TIP60, and
hMOF) acetylate p53 and other transcription factors and function
Table 4
Biological phenotypes of Alpha E6 proteins.
Biological process High-risk HPV E6
(HPV-16, 18, or 31)
Low-risk HPV E6
(HPV-6 or -11)
References
Maintenance of viral genomes + + Oh et al. (2004), Park and Androphy (2002), Thomas et al. (1999)
Genome ampliﬁcation upon differentiation + Wang et al. (2009a)
Inhibition of p53 transactivation + + Crook et al. (1991), Lechner and Laimins (1994), Pim et al. (1994)
Inhibition of p53 acetylation + + Jha et al., (2010), Patel et al. (1999), Thomas and Chiang (2005)
Bypass of growth arrest upon DNA damage + Havre et al. (1995), Kessis et al. (1993), Song et al. (1998)
Induction of genetic instability + Duensing and Munger (2002), Liu et al. (2007), Plug-Demaggio and
McDougall (2002), Schaeffer et al. (2004)
Immortalization of human cells with Rb inactivation + Hawley-Nelson et al. (1989), Hudson et al. (1990), Munger et al. (1989),
Sedman et al. (1991), Woodworth et al. (1989)
Induction of hyperplasia/cancer
in transgenic mice
+ Nguyen et al. (2002), Riley et al. (2003), Shai et al. (2007),
Simonson et al. (2005), Song et al. (2000)
Epithelial to mesenchymal transition/invasion + Krishna Subbaiah et al. (2012), Lopez-Ocejo et al. (2000),
Watson et al. (2003)
NF-kappaB activation + An et al. (2008), James et al. (2006b), Nees et al. (2001), Yuan et al. (2005)
Telomerase activation Gewin and Galloway (2001), Gewin et al. (2004), Kiyono et al. (1998),
Klingelhutz et al., 1996, Veldman et al. (2001), Xu et al. (2008)
Inhibition of keratinocyte differentiation + +/− Alfandari et al. (1999), Duffy et al. (2003), Nees et al. (2000),
Sherman et al. (1997), Sherman and Schlegel (1996)
c-Myc activation + Veldman et al. (2003)
Wnt activation + Bonilla-Delgado et al. (2012), Lichtig et al. (2010)
Inhibition of interferon response + +/− Cordano et al. (2008), Nees et al. (2001); Ronco et al. (1998)
mTORC activation + + Spangle et al. (2012), Spangle and Munger (2010)
miR regulation + Au Yeung et al. (2011), Martinez et al. (2008), McKenna et al. (2010),
Wald et al. (2010)
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and Tip60 acetyltransferases, and interact with p300.
Ada3 (for the yeast alteration/deﬁciency in activation protein)
is a component of yeast HAT complexes, and mammalian Ada3 is a
transcription co-activator for p53 and other cellular transcription
factors such as estrogen receptor and RXR-alpha that are targeted
for degradation by 16E6 and E6AP (Balasubramanian et al., 2002).
RNAi knockdown of hAda3 blocks the acetylation of lysine 382 in
p53, inhibits p53 stabilization, and attenuates p14ARF-induced
senescence (Hu et al., 2009; Kumar et al., 2002; Meng et al., 2004;
Nag et al., 2007; Sekaric et al., 2007; Shamanin et al., 2008; Zeng
et al., 2002). Thus the E6 mediated degradation of Ada3 blocks
p53-mediated transcription and could modulate estrogen effects
in HPV infected cervical cells. The association of cutaneous E6
proteins with Ada3 has also recently been found by enzyme
complementation analysis in mammalian cells (Neveu et al., 2012).
Both low and high risk mucosal HPV E6s are able to interact
with the acetyltransferase TIP60 (Jha et al., 2010). Among other
substrates, TIP60 can acetylate p53 at residue K120. The interac-
tion of E6 with TIP60 destabilizes p53 complexes and effects
regulation of p53 responsive genes. It is interesting to note,
however, that the effects are more speciﬁc to genes involved in
regulating apoptosis than to than those involved in cell cycle
arrest, such as p21. Thus, E6's interaction with TIP60 apparently
ﬁne-tunes its regulation of p53, which could be more important
for the low-risk types since the high-risk types would effectively
degrade p53. However, it was demonstrated that E6's affect on
TIP60 did not depend on binding to E6AP or p53 and, in fact, only
the ﬁrst 43 amino acids of E6 (in the E6* splice variant) were
necessary for the effect. Correlating with the above study, EP400, a
component of the NuA4/TIP60 histone acetyltransferase complex,
was identiﬁed in a genome wide RNAi scan for factors that are
necessary for E2-mediated repression of the high risk HPV-16
early promoter, implicating E6 in a feed-forward regulation of both
basal transcription from the early promoter and possibly E2
mediated repression (Smith et al., 2010).
HrE6 also modulates the function of other chromatin modiﬁers
including CARM1, PRMT1 and SET7 to negatively regulate theiractivity, inhibit p53 activation of transcription and enhance the
degradation of p53 by hrE6 (Hsu et al., 2012).
In addition to targeting RB family members, Adenovirus E1a
modulates transcription through association with p300, prompt-
ing a search for similar interactions in papillomaviruses. In vitro
translated E6 proteins associate in vitro with GST fusions of p300
fragments (Patel et al., 1999) and GST-E6 proteins associate in vitro
with partially puriﬁed p300 preparations (Zimmermann et al.,
1999). Similar in vitro binding experiments showed association of
p300 with BE6 (Zimmermann et al., 2000); in all of these studies,
the association was related to the inhibition of p53 transcriptional
activation independent of p53 degradation, and loss of p53
acetylation. In vitro reconstituted chromatin templates demon-
strated that both high and low risk E6 proteins could repress p53
transcription through inhibition of p300 dependent histone acet-
ylation, thus converting p53 transcription complexes from tran-
scriptional activators to repressors (Thomas and Chiang, 2005).
p300 has been isolated by IP/MS from keratinocytes stably
expressing multiple Beta-type E6's, but among the Alpha E6s only
16E6 associated with p300 (White et al., 2012a). CRPV E6 and the
Beta-papillomavirus HPV-38 E6 association with p300 correlated
with the blockage of p53 acetylation by p300; mutants that failed
to associate with p300 were defective for tumor formation
(Muench et al., 2010). In the case of Beta-type HPV-5 and -8, a
role for this interaction is implicated in degradation of p300,
activating AKT kinase, inhibiting differentiation (Howie et al.,
2011), and mediating the ATR response to UV-induced DNA
damage (Wallace et al., 2012). For HPV-38, the interaction of E6
with p300 appears to be essential for immortalization of kerati-
nocytes by HPV-38 E6/E7 (Muench et al., 2010).
E6 functions in replication
Determining the role of the different viral proteins in the HPV
lifecycle has been somewhat difﬁcult due to the technical pro-
blems associated with establishing HPV replication in vitro. Since
E6 is important for the extension of normal keratinocyte lifespan
(which are notorious for having a short replicative lifespan
Table 5
Phenotypes of point mutations in 16E6.
Mutanta. Binds
LXXLLb
Binds
E6APc
Binds
p53d
Degrades p53e Other phenotypes and notes References
16E6 WT ++++ ++++ ++++ ++++ Extends HEK life span with E7f Nakagawa et al. (1995), Band et al. (1991), Klingelhutz et al. (1996)
Immortalizes mammary epithelial cells (MEC)
Immortalizes keratinocytes with E7
Induces telomerase
F2V +++ ++++ − − Immortalizes MEC Liu et al. (1999); Park and Androphy (2002),Shamanin et al. (2008)
Does not support episomal replication of genome
Degrades Ada3 and blocks p53 acetylation
F2L +++ + Supports episomal replication of genome Liu et al. (1999), Park and Androphy (2002)
D4G ++++ ++++ − − Cooper et al. (2006)
P5R ++++ − − Cooper et al. (2006)
Q6A ++++ ++ ++ Cooper et al. (2006)
E7A ++++ ++++ ++++ Cooper et al. (2006)
R8Q +++ − − Cooper et al. (2006)
8S/9A/10T − − Induces telomerase Klingelhutz et al. (1996)
Does not immortalize keratinocytes with E7 Foster et al. (1994), McMurray and McCance (2004), Mietz et al.
(1992), Park and Androphy (2002)Does not support episomal genome replication
R10A ++ ++++ Zanier et al. (2013)
K11E ++ − − Cooper et al. (2006)
L12S ++++ +/− Cooper et al. (2006)
P13L +++ +/− − Cooper et al. (2006)
C16R − +/− − − Cooper et al. (2006)
C16S +++ ++++ +++ ++ Cooper et al. (2006)
I23V ++++ ++++ + + Cooper et al. (2006)
H24L/I27V +++ +++ +++ Immortalizes MEC Dalal et al. (1996)
Y32A ++++ Zanier et al. (2013)
Y32G +++ ++++ Zanier et al. (2013)
K34E +++ +++ +++ Immortalizes MEC Dalal et al. (1996)
Q35R +++ +++ +++ Immortalizes ME. Dalal et al. (1996)
L37F − + No HEK lifespan extension with E7 Nakagawa et al. (1995)
L37S +/− + +++ at 25C, −
at 37C
Does not degrade p53 early passage Liu et al. (1999), Shamanin et al. (2008), Thomas and Chiang (2005)
Degrades p53 in vivo late passage
Does not degrade ADA3
Induces p21 in UV irradiated cells
E39G ++++ +++ No HEK lifespan extension with E7 Nakagawa et al. (1995)
E42G +++ +++ No HEK lifespan extension with E7 Nakagawa et al. (1995)
Y43G − ++ No HEK lifespan extension with E7 Nakagawa et al. (1995)
D44G − +++ Extends HEK life span with E7 Nakagawa et al. (1995)
F45Y ++++ +++ Crook et al. (1991)
F47Y ++++ +++ Crook et al. (1991)
D49H ++++ +++ Crook et al. (1991),
31E6F45Y,
F47Y, D49H
Fails to support HPV-31 replication Thomas et al. (1999)
F45Y,F47Y,
D49H
− − Blocks induction of p21 in UV irradiated cells Crook et al. (1991), Foster et al. (1994), Thomas and Chiang (2005)
Does not induce telomerase Klingelhutz et al. (1996)
F47L − − + ++ No HEK lifespan extension with E7 Nakagawa et al. (1995)
E49G +++
L50G − − − − Binds CBP but not E6AP or p53 Zimmermann et al. (1999)
Does not degrade ADA3 Shamanin et al. (2008)
L50A − − Zanier et al. (2013)
L50E − Zanier et al. (2013)
I52T ++ ++ + + Cooper et al. (2006)
V53G +++ +++ No HEK lifespan extension with E7 Nakagawa et al. (1995)
Y54D + Induces telomerase but does not degrade p53 in vivo Liu et al. (1999), Shamanin et al. (2008)
Shamanin and Androphy (2004)
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Table 5 (continued )
Mutanta. Binds
LXXLLb
Binds
E6APc
Binds
p53d
Degrades p53e Other phenotypes and notes References
Is defective in p53 degradation and inhibits p53 acetylation, stabilization, and growth
arrest induced by p14ARF. Degrades Ada3
Y54H +++ + +++ at 251C, −
at 371C
Immortalizes MEC Liu et al. (1999), Park and Androphy (2002)
Does not support episomal replication of genome
R55A ++ +++ Zanier et al. (2013)
Y54S ++ + No HEK lifespan extension with E7 Nakagawa et al. (1995)
R55G ++ ++ Extends HEK life span with E7 Nakagawa et al. (1995)
N58G +++ +++ Extends HEK life span with E7 Nakagawa et al. (1995)
C63H +++ Mutation in CXXC Crook et al. (1991)
C63R Supports episomal replication of genome Park and Androphy (2002)
C66G − − Mutation in CXXCg Foster et al. (1994)
S71A ++ +++ Zanier et al. (2013)
Y79N − − − − Cooper et al. (2006)
Y84C +++ +++ +++ Immortalizes MEC
I101V ++ +++ +++ Immortalizes MEC Liu et al. (1999)
R102A − + Zanier et al. (2013)
C103R − − − − Mutation in CXXC Cooper et al. (2006)
C103G ++++ Mutation in CXXC Crook et al., 1991,
Q107R +/− +/− +++ at 251C,
+at 371C
Immortalizes MEC Liu et al. (1999)
L110P +++ + No HEK lifespan extension with E7 Nakagawa et al. (1995)
L110Q − − − Does not degrade p53 early passage Liu et al. (1999), Park and Androphy (2002), Shamanin et al. (2008)
Degrades p53 in vivo late passage
Does not support episomal genome replication
Does not degrade ADA3
C111R − + − − Cooper et al. (2006)
E114G + +++ Nakagawa et al. (1995)
E114A + +++ +++ Immortalizes MEC Liu et al. (1999)
Degrades p53 in vivo
K115E +++ + Nakagawa et al. (1995)
R117G + +++ Extends HEK life span with E7 Nakagawa et al. (1995)
H118D +/− + +++ Immortalizes MEC Liu et al. (1999)
Degrades p53 in vivo
H118N ++ ++ +++ Degrades p53 in vivo Liu et al. (1999)
L119R +++ Liu et al. (1999)
D120G ++++ ++++ Extends HEK life span with E7 Nakagawa et al. (1995)
D120A +++ Liu et al. (1999)
D120T +++ Liu et al. (1999)
R124T +++ Liu et al. (1999)
F125L − +++ ++ − Induces telomerase McMurray and McCance (2004), Cooper et al. (2006), Liu et al. (1999)
F125V − ++ +++ at 251C,−
at 371C
Immortalizes MEC Liu et al. (1999)
Degrades p53 in vivo
N127G + ++ Extends HEK life span with E7 Nakagawa et al. (1995)
N127K +++ Liu et al. (1999)
I128T +/− ++ +++ at 251C, −
at 371C
Immortalizes MEC Liu et al. (1999)
Degrades p53 in vivo
R129A ++++ Zanier et al. (2013)
R129G +++ Zanier et al. (2013)
G130R + Extends HEK life span with E7 Nakagawa et al. (1995)
G130V − Immortalizes keratinocytes with E7 McMurray and McCance (2004), Liu et al. (1999), Shamanin et al.
(2008)Induces telomerase
Does not degrade ADA3
R131A − ++ Zanier et al. (2013)
W132R +/− − − Does not immortalize MEC Dalal et al. (1996)
G134V +/− + +++ at 251C, −
at 371C
Immortalizes MEC Liu et al. (1999), McMurray and McCance (2004), Thomas and Chiang
(2005)
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immortalization function. The low-risk HPVs do not readily extend
the lifespan of keratinocytes. Thus, it is difﬁcult to know whether
the effects that one observes are due to the lack of an important
function in replication or the lack of the ability to extend the
lifespan of the cells. Several groups have been able to get HPVs to
replicate in immortal cells, the caveat being that the immortal cells
generally have active telomerase already and may have a defect in
the p53 pathway. Nevertheless, it does appear that E6 is important
for replication (Oh et al., 2004; Thomas et al., 1999). For HPV-16,
loss of E6 or mutations that result in loss of p53 degradation result
in loss or poor maintenance of HPV genomes (Park and Androphy,
2002). Similar results were found for HPV-11 with missense
mutations in E6 (Oh et al., 2004). Lack of E6 results in accumula-
tion of p53 and a reduction in genome ampliﬁcation (Wang et al.,
2009a). The role of E6 in any function should always be viewed in
the context of E7 expression since the two are expressed together
in cells.
E6, Notch, MAML, and keratinocyte differentiation
Since HPV infects keratinocytes and their life cycle is closely
associated with differentiation, it would be expected that HPV
proteins would affect differentiation. There is considerable evidence
that hrE6 can modulate keratinocyte differentiation (Alfandari et al.,
1999; Sherman et al., 1997). Microarray analysis indicates that
expression of HPV-16 E6 causes down regulation of speciﬁc genes
that are involved in keratinocyte differentiation (Duffy et al., 2003;
Muench et al., 2010). HrE6's ability to down regulate differentiation
speciﬁc genes might delay differentiation until enough genomes
have been replicated for subsequent production of infectious virions.
Part of this effect on differentiation may have to do with E6's ability
to down regulate the Notch pathway, which is a key player in
regulating keratinocyte differentiation.
As discussed above, BE6 and Beta genus HPV cutaneous E6
proteins interact with an acidic LXXLL peptide on MAML1 and
MAML3, precipitating a complex containing the DNA binding
subunit RPB-J and Notch1 and repressing Notch dependent tran-
scriptional activation (Brimer et al., 2012; Meyers et al., 2013;
Rozenblatt-Rosen et al., 2012; Tan et al., 2012). The MAML1 co-
activator is most well known for its function in Notch signaling.
Notch signaling between adjacent cells affects the developmental
fates of those cells, linking the differentiation fate of a given cell to
that of its adjacent neighbor. Notch1 and 2 genes are expressed in
the ﬁrst spinous cell layer and the Notch ligand, Jagged2, is
expressed in the basal layer; signaling to Notch1 in the spinous
cell layer then drives early and late squamous epithelial differ-
entiation (Blanpain et al., 2006; Rangarajan et al., 2001b) (and
reviewed in Watt et al. (2008)). Upon canonical Notch signaling,
the Notch receptor is cleaved by the intramembranous gamma-
secretase protease, liberating the Notch intracellular domain
that forms a complex with the RBP-J DNA binding protein. This
displaces a repressor-histone-deacetylase complex and recruits
the MAML1 co-activator, thus converting the RBP-J complex from a
transcriptional repressor to an activator (Fig. 8 and reviewed in
Tanigaki and Honjo (2010)).
Because Notch signaling is central to squamous differentiation,
all papillomaviruses must have developed strategies that in some
way manipulate Notch signaling. Complete disruption of Notch
signaling in the squamous epithelium of transgenic mice results in
the loss of differentiation and squamous cell cancers, as is also
seen upon tissue speciﬁc Notch deletion (Dotto, 2008; Nicolas
et al., 2003), skin speciﬁc expression of a dominant negative
MAML1 (Proweller et al., 2006), or epithelial deletion of RBP-J
(Blanpain et al., 2006). This demonstrates that Notch signaling is a
tumor suppressor in squamous epithelium. The role of Notch
Fig. 8. Notch signaling in squamous epithelium. Notch signaling is initiated when basal cells that express Notch ligands engage Notch that is expressed in suprabasal cells,
resulting in proteolytic cleavages of Notch and liberation of the Notch intracellular domain (ICD). The ﬁrst cleavage within the extracellular domain is mediated by TACE,
while the second cleavage is mediated by the γ-secretase activity of the presenilin protein complex. The cleaved ICD translocates to the nucleus where it associates with
MAML transactivator proteins RBP-Jk, a DNA-binding subunit, displacing HDAC. This converts the RBP-J complex from a transcriptional repressor to a transcriptional
activator, activating transcription of basic helix–loop–helix transcription repressor factors that are the Notch effectors. Notch signaling occurs both at the basal-spinous cell
junction and in the upper spinous layer where it drives terminal differentiation of the granular layer.
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vated Notch can cooperate with high risk E6+E7 oncoproteins to
transform immortalized HaCat cells (Rangarajan et al., 2001a).
Recent deep sequencing of hrHPV positive and HPV negative
squamous cell head and neck cancers revealed a high frequency
of amino-terminal mis-sense mutations of Notch1 in both cancer
types (Agrawal et al., 2011; Stransky et al., 2011). This suggests that
Notch signaling continues to be a tumor suppressor pathway in
hrHPV cancers and raises the question as to how the Alpha genus
HPVs circumvent the effects of Notch signaling. Terminal differ-
entiation in the squamous superﬁcial layer is necessary to ensure a
competent epithelial barrier, since loss of barrier function would
predictably result in microbial infections and immune cell inﬁltra-
tion of the papilloma. How papillomaviruses repress and delay
spinous differentiation yet allow for terminal corneal differentia-
tion is as yet unclear.
hrE6 can promote the growth of colonies of keratinocytes that
fail to stratify when cell cultures are switched from low to high
calcium media (Sherman et al., 2002, 1997; Sherman and Schlegel,
1996). The failure to stratify is not evident when E6 transduced
colonies are pooled and passaged or when grown in organotypic
cultures. Although a quantitative and intriguing phenotype, more
work is needed to understand what interactions with E6 are
responsible for this phenomenon.
E6, autophagy, and metabolism
E6 is able to stimulate protein synthesis by increasing cap-
dependent translation through enhancement of 5′ mRNA cap
translation initiation complex via activation of mTORC1 (Spangle
and Munger, 2010). Analysis of E6 mutants indicated that pre-
servation of the overall E6 fold to interact with LXXLL motifs was
required, and cutaneous E6s were unable to activate cap-dependent translation (Spangle et al., 2012). 16E6 also effects
PDK1 and mTORC2 to activate Akt, causing subsequent activation
of the mTORC1 pathway. It may be that increasing energy
metabolism could enhance HPV replication since HPVs replicate
in terminally differentiating cells that are likely to have low a
nutrient supply.
Regulation of miRNAs by E6
E6s can regulate the expression of miRNAs in cells (Martinez
et al., 2008; McKenna et al., 2010; Wald et al., 2010; Wang et al.,
2009b). HrE6 down regulates miR-34a, which is involved in
targeting cell cycle control genes (Wang et al., 2009b). There is
also evidence that down regulation of miR-218 by hrE6 is impor-
tant for regulating expression of LAMB3 (Martinez et al., 2008) and
that this may play a role in cervical cancer cell growth. Down
regulation of miR-23b by hrE6 may also be important for regulat-
ing cell migration by causing the up regulation of urokinase
plasminogen activator gene (Au Yeung et al., 2011). It is unknown
how E6 regulates miRNAs but it seems likely that it is through its
interaction with transcriptional factors and signaling proteins.
E6 involvement in regulation of apoptosis and immune response
Like most viruses, HPV can repress the natural response of a
host cell to infection. This is mainly through inhibition of apoptosis
and inhibition of the immune response. The mechanisms are
diverse both in the different pathways that are affected by the
same type and in the ways that different types inhibit apoptosis
and immunity. While there is evidence that viral proteins such as
E2 are involved in modulating the immune response, most studies
have focused on E6 and E7. E6 appears to play a signiﬁcant role.
S.B. Vande Pol, A.J. Klingelhutz / Virology 445 (2013) 115–137 131NF-κB: NF-κB activation is a frequent occurrence in squamous
cell carcinomas and there is strong evidence that it is important
for transformation of epithelial cells (Huber et al., 2004). High-risk
E6s are capable of activating NF-κB (D’Costa et al., 2012; Havard
et al., 2005; James et al., 2006b; Nees et al., 2001; Yuan et al.,
2005). The mechanism is not entirely clear although there is
evidence that it may depend upon the PDZ binding motif (James
et al., 2006b). Another study indicated that hrE6 inactivates a
deubiquitinase called CYLD that causes activation of NF-κB, parti-
cularly in conditions of hypoxia (An et al., 2008), and ﬁnally hrE6's
activate NF-κB through interaction with NFX1-91 (Xu et al., 2010).
There is also evidence that both E6 and E7 from the cutaneous
HPV-38 can activate NF-κB (Hussain et al., 2011). The activation of
NF-κB leads to up regulation of cIAP2, an inhibitor of apoptosis,
which would be expected to confer some resistance to certain DNA
damaging agents (James et al., 2006b; Wu et al., 2010).
The consequences of NF-κB activation by E6 are apparently
complex and may depend on cell type. A recent study indicated
that NF-κB activation by E6 in ectocervical cells increases prolif-
eration, whereas it may be inhibitory to growth of cells that are
derived from the transformative zone, where most cervical cancers
develop (Vandermark et al., 2012).
E6 effects upon apoptosis: Transgenic expression of HPV-16 E6
and E7 in the mouse eye lens induces tumor formation while
expression of E7 induces apoptosis of the developing lens;
apoptosis induced by 16E7 is only partially ablated by p53 null
status, demonstrating that 16E6 possessed both p53 dependent
and p53 independent anti-apoptotic functions (Griep et al., 1993;
Pan and Griep, 1995). Both low and high risk mucosal E6s can bind
to the pro-apoptotic protein Bak to cause its degradation (Thomas
and Banks, 1999). Bak has homology to Bcl-2 and acts at the
mitochondria but has an opposite effect of Bcl-2 with regard to
apoptotic activation (Shamas-Din et al., 2011). Bak causes the
release of cytochrome c and activation of the apoptotic caspase
cascade. Bak is generally sequestered by Mcl-1 and Bcl-XL but is
released upon DNA damage. E6's ability to degrade Bak is inde-
pendent of its p53 degradation function, although p53 activation is
known to activate Bak. A more recent study indicated that E6s
from multiple Beta-papillomavirus types also interact with and
cause the degradation of Bak (Underbrink et al., 2008). In the latter
case, the degradation was found to be dependent on E6AP,
however another study, also using Beta-papillomaviruses, did not
observe a similar dependency (Simmonds and Storey, 2008).
Proteomic studies have not detected speciﬁc interaction of E6
with Bak (White et al., 2012a). The conserved targeting of BAK by
Alpha and Beta papillomaviruses implies a conserved structural
feature of these E6 proteins that has yet to be delineated.
High risk HPV E6s can bind to procaspase 8 which can prevent
E6-expressing cells from responding to apoptotic stimuli
(Tungteakkhun and Duerksen-Hughes, 2008). 16E6 binding to
procaspase 8 leads to a change in the ability of procaspase 8 to
bind to itself or to FADD (Filippova et al., 2007). Interestingly, the
small E6* isoform can also bind to procaspase 8, which seems to
have an opposite effect of stabilizing it rather than accelerating its
degradation; the full-length and E6* forms bind to different sites
of procaspase 8 (Tungteakkhun et al., 2010).
E6 and immune response: Interferon treatment of HPV asso-
ciated lesions has resulted in mixed results (Beglin et al., 2009).
HPV proteins can modulate the response to interferon and in cells
in which HPV has integrated, E6 and E7 are expressed at higher
levels (i.e. in higher grade lesions) and are more resistant to the
effects of interferon. Both E6 and E7 have been implicated in
causing resistance to interferon (Beglin et al., 2009; Nees et al.,
2001). The E6 proteins from both low- and high-risk mucosal
types are able to inhibit the interferon response. E6 causes down
regulation of multiple interferon responsive genes (Nees et al.,2001). Both low- and high-risk mucosal E6s can bind to Tyk2 of
the Jak-Stat pathway (Li et al., 1999). HrE6 binds to IRF3 and
inhibits its ability to activate interferon-responsive genes (Ronco
et al., 1998). E6's ability to interact with p53 and p300/CBP is also
likely to play a role in interferon response regulation (Hebner
et al., 2007). The cutaneous Beta HPV type 38 also interferes with
the interferon pathway (Cordano et al., 2008) apparently by down
modulating STAT-1 expression. Both E6 and E7 are involved in this
process.
Other biological functions of the low risk E6
IP/MS experiments have shown the Alpha group low-risk E6
proteins interact with E6AP (Brimer et al., 2007) and proteasome
subunits (Rozenblatt-Rosen et al., 2012; White et al., 2012a).
Earlier reports have described cellular binding partners for low-
risk E6 proteins, such as zyxin (Degenhardt and Silverstein,
2001a), GPS2 (Degenhardt and Silverstein, 2001b), MCM7
(Kuhne and Banks, 1998; Kukimoto et al., 1998). In addition, there
are discordant observations that high-risk and low-risk forms of
E6 can bind to p73 (Marin et al., 1998; Park et al., 2001). As
discussed above, low risk E6 is required for episomal replication of
low risk HPV-11 genomes (Oh et al., 2004).
GFP fusions to low risk Alpha E6 localize to the cytoplasm (Tao
et al., 2003). There is evidence that low-risk E6's bind to p53 but do
not target its degradation. Transiently expressed low risk E6-GFP
fusion proteins associate with p53 in the cytoplasm and retain p53
there (Sun et al., 2010) and induce p53 dependent apoptosis in HEK
293 or MCF7 cells. In contrast to these observations, examination of
low-risk condylomas show abundant p53 expression in the nucleus
and not the cytoplasm that co-localizes with p21Cip (Giannoudis
and Herrington, 2000; Lassus and Ranki, 1996; Lyman et al., 2008).
Thus, how low-risk E6's may effect p53 function is not entirely clear
but may have to do with regulation of p53 acetylation as has been
discussed.
Several recent publications have elucidated functions of the
long-enigmatic Beta E6 proteins. Beta group HPV's are cutaneous,
and in normal persons are ubiquitous and produce unapparent
cutaneous lesions. In the severely immune-compromised or in
persons with the autosomal recessive condition epidermodyspla-
sia verruciformis, Beta genus HPV produce visible ﬂat warts that
progress to squamous cell carcinomas in sun exposed areas
(reviewed in Orth (2006)). This has given rise to a hypothesis that
the Beta HPVs may predispose to the development of cutaneous
squamous cell carcinomas by preventing the loss of UV damaged
cells that harbor the virus. Correlating with this hypothesis,
various Beta group E6 proteins have been shown to target the
degradation of Bak, abrogate ATR activation, and block protein
acetylation through the degradation of p300, all of which results
in the persistence of UV induced DNA damage (Bedard et al.,
2008; Giampieri et al., 2004; Howie et al., 2011; Jackson et al.,
2000; Jackson and Storey, 2000; Simmonds and Storey, 2008;
Underbrink et al., 2008; Wallace et al., 2012). Unlike squamous cell
carcinomas caused by high risk Alpha HPVs, the genomes of the
Beta HPVs are not typically found in cutaneous squamous cell
cancer cell lines, and the ubiquity of the virus has made the many
studies that detect Beta HPVs by PCR in cancers problematic.Concluding remarks
E6 proteins appear to be extraordinary: how can such a small
protein do so much? Many protein interactions have been
reported, all of which purport to connect in some way to altered
cell physiology, but certainly such a small protein cannot have so
many direct interaction partners! Sorting out which of the effects
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the analysis of E6 phenotypes and interactions is E6 mutants, but
many E6 mutants used in the past (such as deletion mutants) will
turn out to be globally defective for core functions of E6 such as
LXXLL interactions, making conclusions drawn from the use of
these mutants now subject to new interpretation. Extending those
observations to indirect E6 interactions that may underlie its
protean phenotypes is the challenge for the future. The solved
structure of BE6 and 16E6 will now allow a precise mapping of the
functions of E6 to its structure, and also opens the door to the
development of small molecule inhibitors.Acknowledgments
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